REFRACTORY FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Clinical trials for REFRACTORY FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for REFRACTORY FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for tough ovarian cancers: Triple-Drug attack tested

Disease control Ongoing

This study is testing whether combining two or three newer drugs works better than standard chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based drugs. It will involve about 120 women who have alr…

Matched conditions: REFRACTORY FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 02, 2026 15:22 UTC

REFRACTORY FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA

Get alerted when new REFRACTORY FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA trials appear

New hope for tough ovarian cancers: Triple-Drug attack tested